No Data
The increase once exceeded 7%! Cornerstone Pharmaceuticals' CS5001 (ROR1 ADC) showcases the best advantages in its class.
Recently, the American Society of Hematology (ASH) annual meeting was held, as one of the most prestigious international academic conferences in the field of hematology globally, products that can release clinical data at the ASH annual meeting undoubtedly have significant innovativeness and clinical application potential, which also reflects the enterprise's strength in innovative research and development.
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
Stone Pharmaceuticals (02616) announced the latest clinical data of CS5001 for advanced lymphoma at the 66th usa Hematology Conference.
Jinwu Finance News | Cornerstone Pharmaceuticals (02616) announced that the company will present the latest clinical data for its pipeline 2.0 blockbuster product CS5001 (ROR1ADC) targeting lymphoma at the 66th Annual Meeting of the American Society of Hematology (ASH). It has been reported that: 1) CS5001 is currently the first known ROR1 ADC to observe clinical efficacy in both solid tumors and lymphomas. The announcement at this ASH meeting highlights the latest safety and efficacy data of CS5001 as a monotherapy for advanced lymphoma. 2) CS5001 has shown good tolerance in patients with heavily treated advanced B-cell lymphoma.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
CStone Pharmaceuticals Grants Commercial Rights of Tumor Drug for MENA Region to UAE Firm
Cornerstone Pharmaceuticals-B (02616.HK) has reached a global strategy cooperation with Pharmalink regarding Sugrilimab in the Middle East and Africa.
Goldenway November 21st | Base Stone Pharmaceuticals-B (02616.HK) announced that the company has reached a commercial strategic cooperation with Pharmalink Store- L.L.C - O.P.C ("Pharmalink"). Pharmalink is a well-known pharmaceutical company based in the United Arab Emirates. According to the licensing and commercialization agreement, Pharmalink will obtain the commercialization of Shuglie monoclonal antibody in the Middle East and North Africa region, including Saudi Arabia, the United Arab Emirates, Kuwait, Qatar, Oman, Bahrain, Algeria, and Tunisia.
CStone Pharmaceuticals (HKG:2616) Not Doing Enough For Some Investors As Its Shares Slump 34%
No Data
